MindMed
need for additional treatment options is clear individual variations diverse gad is not a once size fits all indication it is a very occurring conditions depression or may complicate treatment resistance fail first line treatment side effects effects which reduce compliance current choices come with the potential for long term side disorder | MindMed
Company
Deck Type
Sector
Industry
Deck date
June 2023
Slide
17 of 61
Related slides by other companies
NeuroSense Therapeutics
Investor Presentation
June 2023
als | NeuroSense Therapeutics
Boundless Bio
IPO
March 2024
overcame amplification based resistance to treatment of cells in | Boundless Bio
Other recent decks by MindMed
See all presentations (10 decks)
Investor Presentation
January 2025
Investor Presentation
December 2024
Investor Presentation
November 2024
Results
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights